SHR-3167
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
November 25, 2025
SHR-3167-201: Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
(clinicaltrials.gov)
- P2 | N=275 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Nov 2025 ➔ Mar 2026
Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 19, 2025
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
(clinicaltrials.gov)
- P2 | N=173 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 11, 2025
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=55 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 07, 2025
A phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety of multiple-dose SHR-3167 injection in type 2 diabetic subjects at steady state.
(ChiCTR)
- P1 | N=50 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; Jiangsu Hengrui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
June 27, 2025
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=55 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 30, 2025
Once-Weekly Insulin SHR-3167 in Healthy Subjects and Type 2 Diabetes Mellitus Participants—A Phase 1, Randomized, Single- and Multiple-Ascending Dose Study
(ADA 2025)
- "Once-weekly insulin SHR-3167 showed good tolerability, favorable pharmacokinetics, and evident glucose-lowering effects."
Clinical • P1 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
March 30, 2025
Once-Weekly Insulin SHR-3167 vs. Insulin Glargine U100 (IGlar U100) in Healthy Subjects
(ADA 2025)
- "The PD/PK profiles, and safety of SHR-3167 support its potential as once-weekly regimen for glycemic management."
Clinical • Hypoglycemia • Metabolic Disorders
June 12, 2025
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
(clinicaltrials.gov)
- P2 | N=153 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 21, 2025
SHR-3167-201: Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
(clinicaltrials.gov)
- P2 | N=273 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 14, 2024
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
(clinicaltrials.gov)
- P2 | N=273 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
October 11, 2023
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 18, 2023
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 12
Of
12
Go to page
1